DAM
NGNE icon

DLD Asset Management’s Neurogene NGNE Stock Holding History

DLD Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,105
Closed -$65K – 94
2018
Q3 		$65K Sell
1,105
-37,050
-97% -$2.19M ﹤0.01% 106
2018
Q2 		$2.03M Buy
38,155
+30,760
+416% +$8.02M 0.15% 79
2018
Q1 		$2.08M Buy
+7,395
New +$2.04M 0.19% 66

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

DLD Asset Management's NGNE Position: Q3 2018 in Review

DLD Asset Management sold out of Neurogene (NGNE) in Q3 2018, closing a stake of 18,995 shares — an estimated $1.12M sold.

DLD Asset Management first reported a position in NGNE in Q2 2018 and held it in 1 quarter. The position peaked at $1.01M in Q2 2018. 45 funds tracked by Wall St. Rank hold NGNE as of Q3 2018.

  • DLD Asset Management reported no remaining Neurogene position as of Q3 2018 after selling out during the quarter.
  • DLD Asset Management sold 18,995 Neurogene shares in Q3 2018, an estimated $1.12M.
  • DLD Asset Management first reported a position in Neurogene in Q2 2018 and held it in 1 quarter.
  • DLD Asset Management's Neurogene position peaked at $1.01M in Q2 2018.
  • 45 funds tracked by Wall St. Rank held Neurogene as of Q3 2018.

Based on DLD Asset Management's 13F filing for Q3 2018, filed 13 Nov 2018.